Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global stem cells market was valued at US$ 10.57 billion in 2020 and is expected to register a revenue CAGR of 7.9% to reach US$ 24.4 billion by 2031.

Stem Cells Market Fundamentals

Stem cells refer to cells with a unique ability to develop into different cell types called daughter cells. These new cells can range from muscle cells to brain cells. They help in replacing damaged cells in the body. There are diverse types of stem cells, such as embryonic stem cells, adult stem cells, induced pluripotent stem cells, and perinatal stem cells. Different types of cells have different origins. For instance, embryonic stem cells are derived from 3 to 5 days old embryos, and adult stem cells are developed from adult tissues, such as bone marrow. Perinatal stem cells are derived from amniotic fluid and umbilical cord blood. As stem cells have the potential to repair damaged tissue, there has been an increase in focus on the study of stem cells to cure various diseases or disorders.

[674523]

Stem Cells Market Dynamics

Growing public-private funding for stem cell research and rising awareness related to therapeutic applications of stem cells are key factors driving the revenue growth in the stem cells market. Moreover, an increase in the prevalence of chronic diseases such as cancer, rise in the number of R&D activities related to stem cells, and increase in demand for regenerative medicine are expected to boost the stem cells market revenue growth during the forecast period.

However, ethical concerns and potential risks of oncogene expression during the reprogramming of the cells are some of the factors likely to hinder the market revenue growth to some extent.

Stem Cells Market Ecosystem

The global stem cells market is analyzed based on four perspectives: cell source, type, application, and region.

Stem Cells Market by Cell Source

Based on the cell source, the stem cells market is segmented into human embryonic stem cells, adult stem cells, induced pluripotent stem cells, and other types of stem cells. 

The adult stem cells segment accounts for the largest share of the stem cells market, due to minimal possibilities of rejection of these cells by the body and high success rate. Adult stem cells are the most used cell type. Moreover, as adult stem cells can be transformed into pluripotent stem cells, they offer more advantages as compared to embryonic cells without affecting the embryo. These factors have resulted in an increase in the usage of these types of cells, thereby contributing to a significant growth of this segment.

Stem Cells Market by Type

Based on the type, the stem cells market is segmented into allogeneic stem cell therapy and autologous stem cell therapy.

The autologous stem cell therapy is expected to be the fastest-growing segment during the forecast period. This can be ascribed to various advantages, such as reduced possibilities of infection from an unknown donor and lower chances of rejection by the body.

Stem Cells Market by Application

[654235]

Based on the application, the stem cells market is segmented into regenerative medicine and drug discovery & development. 

The regenerative medicine segment accounts for the largest revenue share of the stem cells market. Factors attributed to the revenue growth of this segment include a rise in the number of research activities in the field of regenerative medicine using stem cells and increase in the prevalence of cancer. Moreover, growing awareness about the usage of regenerative medicine to replace damaged tissues is projected to drive the segment growth during the forecast period.

Stem Cells Market by Region

Based on the region, the global stem cells market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America accounts for the largest revenue share of the global stem cells market. Major factors ascribed to the revenue growth of the stem cells market in North America include rise in the public-private funding for R&D activities of regenerative medicines, increase in the prevalence of chronic infectious diseases, and presence of prominent players in the region. Moreover, increase in the usage of stem cells in several ongoing studies in the field of oncology, musculoskeletal disorders, and CNS disorders are expected to fuel the market revenue growth during the forecast period.

Stem Cells Market Competitive Landscape

The prominent players operating in the global stem cells market include:

• Pfizer Inc.
• Osiris Therapeutics, Inc. (Smith & Nephew)
• ReNeuron Group plc
• GlaxoSmithKline plc
• Holostem Terapie Avanzate S.r.l.
• Baxter
• AlloSource
• Astellas Pharma Inc.
• Pluristem Therapeutics Inc.
• Regen BioPharma, Inc.

Stem Cells Market Strategic Developments

• In February 2021, Evotec SE entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf for the development of a cell therapy intended for usage in the treatment of heart failure
• In August 2020, Pluristem Therapeutics Inc. signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a healthcare center focused on cell therapy and regenerative medicine
• In May 2020, CiRA Foundation and the Cell and Gene Therapy Catapult launched a new collaborative research project focused on the induced pluripotent stem (iPS) cell characterization. This project is focused on finding applications of iPS cell technologies in the production of regenerative medicine products.
• In April 2020, HebeCell Corp (U.S.) raised US$ 10 million in Pre-Series A financing from Aceso Biotech Venture Fund, to advance their capabilities in the development of natural killer cells (NK cells) engineered human pluripotent stem cells (hPSC) in the U.S. and outside the U.S.
• In April 2020, scientists from the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine were granted immediate FDA authorization for a 24-patient clinical trial to test the safety and efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe the COVID-19 infection.
• In April 2020, Fate Therapeutics entered into a multi-year collaboration with Janssen, a Johnson & Johnson company, for the development of novel iPSC-derived cell-based cancer immunotherapies
• In April 2020, Citius Pharmaceuticals entered into an exclusive 6-month option agreement with Novellus to license novel stem-cell therapy for the acute respiratory distress syndrome (ARDS) associated with COVID-19.
• In March 2020, ElevateBio, a Cambridge-based cell and gene therapy startup, received US$ 170 million in Series B funding

Frequently Asked Questions About This Report